HTD Biosystems

Executive Summary

HTD Biosystems is a privately held contract research and development organization (CRO) and contract development and manufacturing organization (CDMO) based in San Francisco, California. Founded in 2001, the company specializes in biologics formulation, lyophilization, and process development, with a particular focus on proteins, vaccines, liposomes, and lipid nanoparticles (LNPs). Its services span from early discovery through GLP toxicology lot manufacturing, positioning it as a flexible partner for biotech and pharmaceutical firms seeking outsourced development and manufacturing support. Although HTD is pre-clinical stage as a company (its clients' products are at various stages), its established reputation in lyophilization and LNP formulation makes it a key player in the growing biologics and vaccine supply chain. The company's long operating history and customer-centric approach provide a competitive edge in the fragmented CDMO landscape. However, as a private entity with no disclosed funding or valuation, growth visibility is limited. Industry tailwinds from increased biologics development, demand for LNP-based therapies (e.g., mRNA vaccines), and outsourcing trends support HTD's business model.

Upcoming Catalysts (preview)

• Q3 2026Expansion of LNP manufacturing capacity to meet growing mRNA demand65% success
• Q4 2026Strategic partnership with a major biopharma for vaccine formulation development50% success
• TBDAcquisition by a larger CDMO seeking biologics formulation expertise35% success